Medpace Reports Strong Q2 Earnings with Revenue and EPS Growth
Medpace (NASDAQ:MEDP) reported strong second-quarter results, posting a revenue increase of 17.2% to $707.3 million compared to the same period last year. Diluted earnings per share rose to $4.25 from $3.10 in Q2 2025 as net income jumped by 34.5%. The company attributed its improved performance to lower cancellations and higher interest income, which boosted profitability despite a stable EBITDA margin of 21.7%. Bookings also reached record levels with net new business awards rising 28.2% year-over-year to $795.7 million, resulting in a book-to-bill ratio of 1.13. Ending backlog stood at approximately $3 billion as of June 30, up from the prior year. Management expects about $1.96 billion of this backlog to convert into revenue over the next 12 months. For full-year 2026 guidance, Medpace now anticipates revenue between $2.805 billion and $2.885 billion with EPS expected in a range from $17.25 to $17.95.
Tickers: $MEDP